logo-loader
viewAdial Pharmaceuticals Inc

Adial Pharmaceuticals looks to apply its alcohol-use disorder drug to opioid-use disorder

A Phase 2b clinical trial of AD04 showed 'promising results' in treating patients with alcohol-use disorder

Bottle of prescription pills spilled onto the table
The CDC estimates that 72,000 people in the US died of drug overdoses in 2017

Adial Pharmaceuticals Inc (NASDAQ:ADIL) plans to expand the potential of its lead drug AD04, designed to treat alcohol-use disorder, to benefit patients with opioid-use disorder.

A Phase 2b clinical trial of the drug showed “promising results” in treating patients with alcohol use disorder, reducing the frequency and quantity of drinking without any serious adverse effects reported.

Shares more than doubled by Thursday’s closing bell, dipping around 8% to $3.85 in Friday pre-market trading.

READ: Anavex Life Sciences doses patients in Phase 2 ANAVEX2-73 Parkinson disease dementia study

 “We are expanding our activities around AD04 to include opioid use disorder (OUD) and believe this program has significant potential since the physiology and neuro-transmitters involved in opioid addiction are similar to alcohol and could be expected to be modulated by a serotonin-3 receptor antagonist,” said CEO William Stilley in the company’s press statement.

The company is hopeful that AD04 can bring something to the table in an underserved market as the use of opioid and synthetic opioids, such as fentanyl, continue to contribute to overdose deaths in the US.

The Centers for Disease Control estimate that 72,000 people in the US died of drug overdoses in 2017, linking two-thirds of those deaths to opioids.

The clinical-stage biopharmaceutical company focuses on the development of treatments for addictions.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

 

Quick facts: Adial Pharmaceuticals Inc

Price: 1.86 USD

NASDAQ:ADIL
Market: NASDAQ
Market Cap: $25.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Alpha Growth PLC using experienced team to start Alpha Growth and Income...

Alpha Growth PLC (LON: ALGW) CEO Gobind Sahney joined Steve Darling from Proactive to discuss the fund called Alpha Growth and Income fund or AGI. This funds prospective client are family offices, pension funds, and other institutions that still wish to receive some income but also want their...

1 day, 6 hours ago

2 min read